Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AVIR Stock Forecast 2026-2027
$4.35
Current Price
$348.12M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to AVIR Price Targets
+129.9%
To High Target of $10.00
+129.9%
To Median Target of $10.00
+37.9%
To Low Target of $6.00
AVIR Price Momentum
-0.2%
1 Week Change
+6.1%
1 Month Change
+36.4%
1 Year Change
+21.8%
Year-to-Date Change
-32.6%
From 52W High of $6.45
+56.5%
From 52W Low of $2.78
📊 TOP ANALYST CALLS
Did AVIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Atea is one of their latest high-conviction picks.
Latest AVIR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AVIR has a bullish consensus with a median price target of $10.00 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $4.35, the median forecast implies a 129.9% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Miller at Evercore ISI Group, projecting a 129.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVIR Analyst Ratings
2
Buy
1
Hold
0
Sell
AVIR Price Target Range
Low
$6.00
Average
$10.00
High
$10.00
Current: $4.35
Latest AVIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | Evercore ISI Group | Jonathan Miller | Outperform | Maintains | $10.00 |
| Apr 11, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | Upgrade | $N/A | |
| Aug 10, 2023 | JP Morgan | Underweight | Downgrade | $N/A | |
| Mar 16, 2023 | JP Morgan | Neutral | Maintains | $N/A | |
| Jan 27, 2023 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Jan 24, 2023 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Aug 15, 2022 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Mar 2, 2022 | JP Morgan | Neutral | Maintains | $N/A | |
| Mar 1, 2022 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Feb 16, 2022 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Jan 6, 2022 | Morgan Stanley | Underweight | Downgrade | $N/A | |
| Nov 18, 2021 | SVB Leerink | Market Perform | Downgrade | $N/A | |
| Oct 20, 2021 | SVB Leerink | Outperform | Maintains | $N/A | |
| Oct 20, 2021 | JP Morgan | Neutral | Downgrade | $N/A | |
| Oct 5, 2021 | Morgan Stanley | Equal-Weight | Downgrade | $N/A | |
| Sep 9, 2021 | SVB Leerink | Outperform | Initiates | $N/A | |
| Aug 18, 2021 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jun 3, 2021 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Apr 6, 2021 | Morgan Stanley | Overweight | Maintains | $N/A |
Atea Pharmaceuticals Inc (AVIR) Competitors
The following stocks are similar to Atea based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Atea Pharmaceuticals Inc (AVIR) Financial Data
Atea Pharmaceuticals Inc has a market capitalization of $348.12M with a P/E ratio of -2.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -52.6%.
Valuation Metrics
Market Cap
$348.12M
Enterprise Value
$92.75M
P/E Ratio
-2.2x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+73.5%
Current Ratio
7.9x
Debt/Equity
0.3x
ROE
-52.6%
ROA
-33.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atea Pharmaceuticals Inc (AVIR) Business Model
About Atea Pharmaceuticals Inc
What They Do
Develops oral antiviral therapeutics for viral infections.
Business Model
Atea Pharmaceuticals focuses on the discovery and development of oral antiviral drugs, generating revenue primarily through the commercialization of its drug candidates. The company is advancing multiple products through various stages of clinical trials, including bemnifosbuvir for COVID-19 and a combination therapy for hepatitis C, aiming to secure partnerships and licensing agreements to enhance its market position.
Additional Information
Founded in 2012 and headquartered in Boston, Massachusetts, Atea Pharmaceuticals operates in the biotechnology sector and holds a license agreement with MSD International GmbH for the development and commercialization of its hepatitis C treatment, indicating strategic collaborations that may support its growth.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Dr. Jean-Pierre Sommadossi Ph.D.
Country
United States
IPO Year
2020
Website
ateapharma.comAtea Pharmaceuticals Inc (AVIR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Jun 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Atea Pharmaceuticals (AVIR) and Design Therapeutics (DSGN) performance metrics are compared to their sector's performance year-to-date. Specific figures were not provided in the excerpt.
Why It Matters
Performance comparisons indicate how Atea Pharmaceuticals and Design Therapeutics are faring relative to their sector, influencing investor sentiment and potential investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Atea Pharmaceuticals receives a buy rating as it prepares for pivotal phase 3 data on its BEM/RZR hepatitis C treatment expected in mid-2026. The company has $256M cash through 2027.
Why It Matters
Atea's buy rating reflects optimism about its potential HCV treatment, but success in phase 3 is critical for its market position against major competitors, shaping future stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Atea Pharmaceuticals reported positive Phase 1 results for its HCV treatment, bemnifosbuvir and ruzasvir (BEM/RZR), showing low drug-drug interaction risk with common medications.
Why It Matters
Positive Phase 1 results for Atea's BEM/RZR highlight its potential in treating hepatitis C with minimal drug interactions, enhancing marketability and investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Atea Pharmaceuticals (AVIR) is considered technically oversold, suggesting reduced selling pressure. Wall Street analysts are revising earnings estimates upward, indicating a potential trend reversal.
Why It Matters
Atea Pharmaceuticals is showing signs of an oversold condition, suggesting a potential rebound. Analysts' positive revisions in earnings estimates further support a bullish outlook.
Source: Zacks Investment Research
Market Sentiment:
Positive
Atea Pharmaceuticals Q1 Earnings Call Highlights
1 month ago
Quick Summary
Atea Pharmaceuticals (NASDAQ: AVIR) is on schedule for two Phase 3 hepatitis C readouts in 2026 and is advancing a hepatitis E program for immunocompromised patients.
Why It Matters
Atea's successful Phase 3 readouts could boost stock value and validate its hepatitis C and E programs, attracting investor interest in its potential market impact and innovation.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Atea Pharmaceuticals, Inc. (AVIR) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details on revenue and projections were provided.
Why It Matters
Atea Pharmaceuticals' Q1 2026 earnings provide insights into financial performance and growth prospects, impacting stock valuation and investor sentiment towards the company.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About AVIR Stock
What is Atea Pharmaceuticals Inc's (AVIR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Atea Pharmaceuticals Inc (AVIR) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $6.00.
Is AVIR stock a good investment in 2026?
According to current analyst ratings, AVIR has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVIR stock?
Wall Street analysts predict AVIR stock could reach $10.00 in the next 12 months. This represents a 129.9% increase from the current price of $4.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atea Pharmaceuticals Inc's business model?
Atea Pharmaceuticals focuses on the discovery and development of oral antiviral drugs, generating revenue primarily through the commercialization of its drug candidates. The company is advancing multiple products through various stages of clinical trials, including bemnifosbuvir for COVID-19 and a combination therapy for hepatitis C, aiming to secure partnerships and licensing agreements to enhance its market position.
What is the highest forecasted price for AVIR Atea Pharmaceuticals Inc?
The highest price target for AVIR is $10.00 from Jonathan Miller at Evercore ISI Group, which represents a 129.9% increase from the current price of $4.35.
What is the lowest forecasted price for AVIR Atea Pharmaceuticals Inc?
The lowest price target for AVIR is $6.00 from at , which represents a 37.9% increase from the current price of $4.35.
What is the overall AVIR consensus from analysts for Atea Pharmaceuticals Inc?
The overall analyst consensus for AVIR is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are AVIR stock price projections?
Stock price projections, including those for Atea Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 10:53 AM UTC